Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Adverse events associated with treatment · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Adverse events associated with treatment · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome: adverse events (skin sensitisation at 2 months) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome: adverse events (assessed at 3 months as minimum, moderate or severe) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review